Bright Streak Appears Over US During Aurora Storm, Mystifying Skywatchers
That was a night for auroral activity, as Earth's magnetic field was buffeted by an influx of particles ejected from the Sun several days earlier. Initially, explanations favored STEVE, the name given to the white-mauve streaks of light emitted by rivers of charged particles flowing through Earth's ionosphere.
STEVE is not an aurora, but, like the auroral displays it often appears alongside, is also a product of space weather.
Spoiler though: the light was not actually STEVE, but a rocket stage dumping out methalox rocket fuel at an altitude of about 250 kilometers (155 miles), bang in the ionosphere, according to astronomer Jonathan McDowell, who tracks activity in Earth space.
At 04:12 UTC, Beijing-based startup LandSpace Technology launched its new Zhuque-2E Y2 methane-fueled carrier rocket, bearing six satellites into Earth orbit. About an hour later, the bright stripe appeared in the sky – not far from midnight over much of the US. That stripe, according to McDowell, was the result of a fuel dump from the rocket's upper stage.
Rocket fuel made from methane and liquid oxygen, known as methalox, is a relatively recent development; LandSpace was the first company to successfully launch a methalox rocket, back in 2023, and this is the fifth flight for its Zhuque-2 series, the company said in a statement.
Methalox is attractive to the aerospace industry because it is cheaper, cleaner, and easier to store, and it may be able to be produced on Mars. That would make crewed missions to the red planet more efficient, since the spacecraft would not need to carry the fuel for the return journey from the outset.
Rocket fuel can glow in the upper atmosphere through several mechanisms. One, seen close to twilight hours, is the illumination of ice particles by the light of the Sun. Closer to midnight, the Sun would be too far around the other side of Earth to be able to illuminate particles, even those high in the atmosphere.
In the ionosphere, molecules involving carbon, hydrogen, and oxygen can generate chemical reactions that produce light. Carbon and hydrogen are the components of methane.
"The reactions [of rocket fuel] with the plasma in the ionosphere include ion-molecule charge exchange, electron-ion recombination, and optical emissions from chemiluminescence," a team of physicists led by Paul Bernhardt of the US Naval Research Laboratory explained in a 2012 paper.
"If the plume is fired into the ionosphere at night, chemiluminescent reactions with ion-molecule charge exchange followed by electron-ion dissociative recombination yield a long-lived glow that can be observed from ground or space."
Anybody know what this light could be? byu/Ambitious_Amount_357 inAstronomy
Usually, the glowing fuel of a rocket blasting into space manifests as a strange spiral in the sky. Rocket fuel masquerading as STEVE is a new experience, but it sure is pretty.
Methalox is gaining traction, with more rocket companies investigating its use. Perhaps more such streaks will appear in the sky. If you see one, now you might know what you're looking at.
TRAPPIST-1 Planets Could Be Swimming in Water, Study Shows
Unknown Species of Bacteria Discovered in China's Space Station
NASA Mission Captures Eerie New View of The Moon And Sun
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
7 hours ago
- Business Insider
Savara publishes IMPALA-2 clinical trial results in NEJM
Savara (SVRA) announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript will appear in the online version of the publication. Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the company's corporate website. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>


Indianapolis Star
8 hours ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.

11 hours ago
China rushes to build out solar, emissions edge downward
TALATAN, China -- High on the Tibetan plateau, Chinese government officials last month showed off what they say will be the world's largest solar farm when completed — 610 square kilometers (235 square miles), the size of the American city of Chicago. China has been installing solar panels at a blistering pace, far faster than anywhere else in the world, and the investment is starting to pay off. A study released Thursday found that the country's carbon emissions edged down 1% in the first six months of the year compared to a year earlier, extending a trend that began in March 2024. The good news is China's carbon emissions may have peaked well ahead of a government target of doing so before 2030. But China, the world's biggest emitter of greenhouse gases, will need to bring them down much more sharply to play its part in slowing global climate change. For China to reach its declared goal of carbon neutrality by 2060, emissions would need to fall 3% on average over the next 35 years, said Lauri Myllyvirta, the Finland-based author of the study and lead analyst at the Centre for Research on Energy and Clean Air. 'China needs to get to that 3% territory as soon as possible,' he said. China's emissions have fallen before during economic slowdowns. What's different this time is electricity demand is growing — up 3.7% in the first half of this year — but the increase in power from solar, wind and nuclear has easily outpaced that, according to Myllyvirta, who analyzes the most recent data in a study published on the U.K.-based Carbon Brief website. 'We're talking really for the first time about a structural declining trend in China's emissions,' he said. China installed 212 gigawatts of solar capacity in the first six months of the year, more than America's entire capacity of 178 gigawatts as of the end of 2024, the study said. Electricity from solar has overtaken hydropower in China and is poised to surpass wind this year to become the country's largest source of clean energy. Some 51 gigawatts of wind power was added from January to June. Li Shuo, the director of the China Climate Hub at the Asia Society Policy Institute in Washington, described the plateauing of China's carbon emissions as a turning point in the effort to combat climate change. 'This is a moment of global significance, offering a rare glimmer of hope in an otherwise bleak climate landscape,' he wrote in an email response. It also shows that a country can cut emissions while still growing economically, he said. But Li cautioned that China's heavy reliance on coal remains a serious threat to progress on climate and said the economy needs to shift to less resource-intensive sectors. 'There's still a long road ahead,' he said. A seemingly endless expanse of solar panels stretches toward the horizon on the Tibetan plateau. White two-story buildings rise above them at regular intervals. Sheep graze on the scrubby vegetation that grows under them. Solar panels have been installed on about two-thirds of the land. When completed, it will have more than 7 million panels and be capable of generating enough power for 5 million households. Like many of China's solar and wind farms, it was built in the relatively sparsely populated west. A major challenge is getting electricity to the population centers and factories in China's east. 'The distribution of green energy resources is perfectly misaligned with the current industrial distribution of our country,' Zhang Jinming, the vice governor of Qinghai province, told journalists on a government-organized tour. Part of the solution is building transmission lines traversing the country. One connects Qinghai to Henan province. Two more are planned, including one to Guangdong province in the southeast, almost at the opposite corner of the country. Making full use of the power is hindered by the relatively inflexible way that China's electricity grid is managed, tailored to the steady output of coal plants rather than more variable and less predictable wind and solar, Myllyvirta said. 'This is an issue that the policymakers have recognized and are trying to manage, but it does require big changes to the way coal-fired power plants operate and big changes to the way the transmission network operates,' he said. 'So it's no small task.' ___